Drug Shortage Report for VIMPAT
Report ID | 225092 |
Drug Identification Number | 02357666 |
Brand name | VIMPAT |
Common or Proper name | Vimpat IV 10mg/mL |
Company Name | UCB CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | LACOSAMIDE |
Strength(s) | 10MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 5 Vials |
ATC code | N03AX |
ATC description | ANTIEPILEPTICS |
Reason for shortage | Requirements related to complying with good manufacturing practices. |
Anticipated start date | 2024-04-15 |
Actual start date | 2024-04-10 |
Estimated end date | 2024-04-17 |
Actual end date | 2024-04-16 |
Shortage status | Resolved |
Updated date | 2024-04-17 |
Company comments | No risk to product integrity, patient safety or patient access. Delay in release due to QA operations change. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 2201 BRISTOL CIRCLE OAKVILLE, ONTARIO CANADA L6H 0J8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v5 | 2024-04-17 | French | Compare |
v4 | 2024-04-17 | English | Compare |
v3 | 2024-04-12 | French | Compare |
v2 | 2024-04-12 | English | Compare |
v1 | 2024-04-12 | English | Compare |
Showing 1 to 5 of 5